Onderneming NGM Biopharmaceuticals, Inc.
Aandelen
NGM
US62921N1054
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,59 USD | -1,85% | +1,92% | +85,10% |
Vakgebied
Aantal werknemers: 138
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Medicines
100,0
%
| 55 | 100,0 % | 4 | 100,0 % | -92,02% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 55 | 100,0 % | 4 | 100,0 % | -92,02% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 02-03-15 |
William Rieflin
CHM | Chairman | 64 | 01-09-10 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-08 |
William Chang
CTO | Chief Tech/Sci/R&D Officer | - | 01-02-19 |
Hsiao Lieu
CTO | Chief Tech/Sci/R&D Officer | 53 | 01-03-19 |
Valerie Pierce
CMP | Compliance Officer | 61 | 29-10-19 |
David Goeddel
BRD | Director/Board Member | 72 | 01-01-08 |
Joyce Q. Acbay
LAW | General Counsel | - | 01-04-20 |
Irene Perlich
AUD | Comptroller/Controller/Auditor | - | 01-03-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 71 | 08-06-21 | |
David Goeddel
BRD | Director/Board Member | 72 | 01-01-08 |
William Rieflin
CHM | Chairman | 64 | 01-09-10 |
Director/Board Member | 58 | 01-08-18 | |
Shelly Guyer
BRD | Director/Board Member | 63 | 03-12-19 |
David Woodhouse
CEO | Chief Executive Officer | 54 | 02-03-15 |
Carole Ho
BRD | Director/Board Member | 51 | 05-06-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 83 462 408 | 64 291 519 ( 77,03 %) | 0 | 77,03 % |
Bedrijfsgegevens
NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
94080-7014, South San Francisco
+650 243 5555
http://www.ngmbio.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+85,10% | 133 mln. | |
+2,73% | 108 mld. | |
+9,59% | 103 mld. | |
+6,58% | 23,48 mld. | |
-12,59% | 21,93 mld. | |
-3,29% | 19,68 mld. | |
-36,53% | 18,37 mld. | |
-13,29% | 16,33 mld. | |
+4,68% | 13,72 mld. | |
+34,25% | 12,15 mld. |
- Beurs
- Aandelen
- Aandeel NGM Biopharmaceuticals, Inc. - Nasdaq
- Onderneming NGM Biopharmaceuticals, Inc.